Krystal Biotech, Inc. (KRYS) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Pittsburgh, PA, United States. El CEO actual es Krish S. Krishnan.
KRYS tiene fecha de IPO 2017-09-20, 275 empleados a tiempo completo, cotiza en el NASDAQ Global Market, una capitalización de mercado de $7.89B.
Krystal Biotech, Inc. is a clinical-stage biotechnology company developing redosable gene therapy treatments for serious rare diseases. The company's lead product candidate, beremagene geperpavec (B-VEC), is in Phase III clinical trials for dystrophic epidermolysis bullosa, with additional pipeline programs targeting congenital ichthyosis, aged skin conditions, cystic fibrosis, and Netherton syndrome at various development stages. Founded in 2015 and headquartered in Pittsburgh, Pennsylvania, Krystal Biotech focuses on addressing unmet medical needs in dermatological and genetic disorders through innovative gene therapy approaches.
